17-01-2020

18 L. Kaklamanis - WHO lung cancer histological classification.

18 L. Kaklamanis - WHO lung cancer histological classificati...

19 I. Gkiozos - Update on TNM staging system.

19 I. Gkiozos - Update on TNM staging system.

20 K. Tavernaraki - Radiomics: images are more than pictures.

20 K. Tavernaraki - Radiomics: images are more than pictures...

21 Discussion

22 I. Kotteas - Is there a role for I-O monotherapy in the 1st Line mNSCLC?

22 I. Kotteas - Is there a role for I-O monotherapy in the 1...

23 V. Ramfidis - Is there a role for immunotherapy in the 2nd line mNSCLC?

23 V. Ramfidis - Is there a role for immunotherapy in the 2n...

24 A. Charpidou - Integration of immunotherapy in localized NSCLC.

24 A. Charpidou - Integration of immunotherapy in localized...

25 F. Yumuk - Optimal systemic treatment of patients with CNS involvement.

25 F. Yumuk - Optimal systemic treatment of patients with CN...

26 Discussion

27 S. Lampaki - Planning the therapeutic journey to maximize the treatment outcomes in EGFR (+) NSCLC patients.

27 S. Lampaki - Planning the therapeutic journey to maximize...

28A. Asimakopoulou - Endocrinologic toxicity of ICIs.

28A. Asimakopoulou - Endocrinologic toxicity of ICIs.

29 D. Vassos - Pulmonary toxicity of ICIs.

29 D. Vassos - Pulmonary toxicity of ICIs.

30 D. Mandellos - Neurologic toxicity of ICIs.

30 D. Mandellos - Neurologic toxicity of ICIs.

31 A. Papaspiliou - Cases of special interest.

31 A. Papaspiliou - Cases of special interest.

32 E. Gӧker - Optimal 1st line treatment for mutation naive patients.

32 E. Gӧker - Optimal 1st line treatment for mutation naive...

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016

livemed white